Open AccessUtilization of anti–factor Xa levels to guide reversal of oral factor Xa inhibitors in the emergency department
Author(s) -
Anne Zepeski,
Brett Faine,
Anna E. Merrill,
Grerk Sutamtewagul,
Sharathkumar Bhagavathi
Publication year - 2021
Publication title -
american journal of health-system pharmacy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.487
H-Index - 96
eISSN - 1535-2900
pISSN - 1079-2082
DOI - 10.1093/ajhp/zxab326
Subject(s) - rivaroxaban , medicine , apixaban , interquartile range , emergency department , prothrombin complex , prothrombin complex concentrate , warfarin , emergency medicine , anesthesia , atrial fibrillation , coagulation , psychiatry
Oral factor Xa inhibitors (FXaIs) are increasingly utilized for outpatient anticoagulation therapy; however, laboratory monitoring is not routinely used to assess the safety and efficacy of these agents. We aimed to evaluate the role of chromogenic anti-factor Xa (anti-Xa) assays in the emergency department (ED) in the setting of patients with an acute bleed or requiring emergent procedures.